business
Madrigal Secures Major Deal to Battle Liver Disease
February 11, 2026
A Chinese biotech company in Suzhou has given an American firm the worldwide rights to create and sell six new RNA medicines aimed at a serious liver condition. The deal brings an upfront cash payment of $60 million and could grow to nearly $4. 5 billion if the medicines reach several key develop
